Comparative Pharmacology
Head-to-head clinical analysis: LARIAM versus MALARONE PEDIATRIC.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LARIAM versus MALARONE PEDIATRIC.
LARIAM vs MALARONE PEDIATRIC
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Mefloquine is a 4-quinolinemethanol antimalarial agent that acts as a blood schizontocide. Its exact mechanism is unknown, but it is thought to inhibit heme polymerase, leading to toxic accumulation of free heme in the parasite.
MALARONE PEDIATRIC is a fixed-dose combination of atovaquone and proguanil. Atovaquone selectively inhibits the mitochondrial electron transport chain of Plasmodium species at the cytochrome bc1 complex, collapsing mitochondrial membrane potential and disrupting pyrimidine synthesis. Proguanil is a prodrug converted to cycloguanil, which inhibits dihydrofolate reductase in the parasite, blocking DNA synthesis. The combination synergistically kills blood-stage schizonts and inhibits liver-stage hypnozoites of P. falciparum.
For malaria prophylaxis: 250 mg (base) orally once weekly starting 1-2 weeks before travel, continuing weekly during stay and for 4 weeks after leaving endemic area. For malaria treatment: 1250 mg (base) orally as a single dose, divided if needed (750 mg followed by 500 mg after 6-12 hours). Route: oral. Frequency: weekly for prophylaxis; single dose for treatment.
Adults: 250 mg atovaquone/100 mg proguanil orally once daily for 3 consecutive days for treatment; for prophylaxis, 250 mg/100 mg orally once daily starting 1-2 days before travel and continued for 7 days after leaving endemic area.
None Documented
None Documented
Terminal elimination half-life: approximately 3 weeks (range 13–33 days); prolonged due to extensive tissue distribution and slow release from erythrocytes.
Atovaquone: terminal half-life 1.5-3 days (range 2-3 days in adults, longer in children). Proguanil: terminal half-life 12-21 hours (parent drug) and 14-23 hours (cycloguanil). Clinically, atovaquone's long half-life supports single daily dosing.
Hepatic metabolism (primarily CYP3A4) followed by biliary/fecal elimination; ~40% unchanged in feces, ~9% as metabolites in urine, minimal renal excretion of parent drug (<5%).
Atovaquone: >90% excreted unchanged in feces via biliary elimination; <1% renal. Proguanil: ~40-60% excreted renally as unchanged drug and active metabolite cycloguanil; ~30% fecal.
Category C
Category C
Antimalarial
Antimalarial